trending Market Intelligence /marketintelligence/en/news-insights/trending/z4uW1V3dI2Mlj3B-f6k88A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Marinus seeks to raise $65M via common stock offering, private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Marinus seeks to raise $65M via common stock offering, private placement

Marinus Pharmaceuticals Inc. plans to raise about $65 million in gross proceeds from a public offering of its common stock and a concurrent private placement.

The Radnor, Pa.-based pharmaceuticals company is offering 28 million shares for $1.25 each as part of its underwritten public offering. Underwriters have also been given a 30-day option to buy up to an additional 4.2 million common shares from the company, Marinus said in a Dec. 11 press release.

Meanwhile, certain investors have agreed to purchase a total of $30 million worth of preferred shares.

Net proceeds from the common stock offering and the private placement will be primarily used to further the clinical development of the company's postpartum depression drug ganaxolone, which failed to best placebo during the second part of a mid-stage clinical trial in July.

Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. were the joint book-running managers, while Craig-Hallum Capital Group LLC acted as co-manager for the offering, expected to close Dec. 13.